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Strengths and limitations of this study
 ► The trial has a randomised, controlled design, which 
should minimise bias.
 ► A limited number of well- trained, certified staffs will 
be involved in cervical length measurement, pessary 
and cerclage placement which increases the validity 
of the study.
 ► An open design, which is unavoidable due to the na-
ture of the interventions, could introduce bias.
 ► The majority of women with twin pregnancies in-
volving in the trial will conceive from assisted repro-
ductive technology. Therefore, the external validity of 
the study might be compromised.
AbStrACt
Introduction Women with twin pregnancies and a short 
cervix are at increased risk for preterm birth (PTB). Given 
the burden of prematurity and its attendant risks, the 
quest for effective interventions in twins has been an 
area of considerable research. Studies investigating the 
effectiveness of cervical cerclage, cervical pessary and 
vaginal progesterone in preventing PTB have yielded 
conflicting results. The aim of this study is to compare the 
effectiveness of cervical pessary and cervical cerclage 
with or without vaginal progesterone to prevent PTB in 
women with twin pregnancies and a cervical length (CL) 
≤ 28 mm.
Methods and analysis This multicentre, randomised 
clinical trial will be conducted at My Duc Hospital and My 
Duc Phu Nhuan Hospital, Vietnam. Asymptomatic women 
with twin pregnancies and a CL ≤28 mm, measured at 16–22 
weeks’ gestation, will be randomised in a 1:1:1:1 ratio to 
receive a cerclage, pessary, cerclage plus progesterone or 
pessary plus progesterone. Primary outcome will be PTB <34 
weeks. Secondary outcomes will be maternal and neonatal 
complications. We preplanned a subgroup analysis according 
to CL from all women after randomisation and divided into 
four quartiles. Analysis will be conducted on an intention- to- 
treat basis. The rate of PTB <34 weeks’ gestation in women 
with twin pregnancies and a cervix ≤28 mm and treated 
with pessary in our previous study at My Duc Hospital was 
24.2%. A sample size of 340 women will be required to show 
or refute that cervical cerclage decreases the rate of PTB 
<34 weeks by 50% compared with pessary (from 24.2% to 
12.1%, α level 0.05, power 80%, 5% lost to follow- up and 
protocol deviation). This study is not to be powered to assess 
interactions between interventions.
Ethics and dissemination Ethical approval was obtained 
from the Institutional Ethics Committee of My Duc Hospital 
and informed patient consent was obtained before study 
enrolment. Results of the study will be submitted for 
publication in a peer- reviewed journal.
trial registration number NCT03863613 (date of 
registration: 4 March 2019).
IntroduCtIon
Preterm birth (PTB) is the most common 
cause of neonatal morbidity and mortality 
worldwide1 2 and the second leading cause of 
death in children under 5 years.3 4 Children 
who survive may face the risk of significant 
disability, including cerebral palsy, intellectual 
impairment, chronic lung disease and vision 
and hearing loss for a lifetime. They are also 
at greater risk of developing hypertension, 
diabetes and development problems later 
in their lives.5 Therefore, prevention of PTB 
has been considered a priority worldwide to 
promote the well- being of mothers and chil-
dren.6 Due to an increased use of assisted 
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older maternal age, the incidence of twin pregnancies 
has increased, in the recent three decades, by almost 70% 
worldwide.7 8
Women with twin pregnancies are at increased risk for 
PTB. In the USA, data in 2016 showed that more than 60% 
women with twin pregnancies gave birth before 37 weeks, 
of whom 21.2% did so before 34 weeks.9 Corresponding 
figures in women with singleton pregnancies were 8% and 
2.1%, respectively.9 In addition, short cervical length (CL) 
in the second trimester of pregnancy is well known to be an 
independent risk factor for PTB.10 11 In women with twin 
pregnancies, the risk of spontaneous PTB also increases 
with decreasing CL.12 Therefore, women with twin preg-
nancies and a short cervix are at extremely high risk for 
PTB.13
Although vaginal progesterone, cervical cerclage and 
cervical pessary have been used in clinical practice to 
prevent PTB, evidence regarding the effectiveness of 
these interventions is still inconclusive.14 A meta- analysis 
of randomised clinical trials (RCTs) suggested that proges-
terone potentially reduced PTB and neonatal complica-
tions in women with twin pregnancies and a short cervix.15 
However, a recent meta- analysis showed that progesterone 
could only improve some secondary outcomes, regardless 
of CL.16
For cervical cerclage, a meta- analysis of three trials in 
49 women with twin pregnancies and a CL <25 mm could 
not demonstrate a benefit of cerclage in this popula-
tion.17 Moreover, cerclage group had higher rates of very 
low birth weight and of respiratory distress syndrome 
than control group. In contrast, a recent systematic 
review and meta- analysis, which includes RCTs and 
cohort studies, indicate that cerclage placement is bene-
ficial for the reduction of PTB only in twin pregnancies 
with a CL <15 mm or dilated cervix of >10 mm.18 In this 
study, authors stated that further high- quality studies are 
needed to confirm the findings, due to the insufficiency 
of strong supporting evidence.18
Among types of cervical pessaries, the Arabin is the most 
common used in the prevention of PTB.19 This pessary 
has shown encouraging results in women with twin preg-
nancies. A large open- label RCT was conducted at 40 
Dutch centres from 2009 to 2012 among 813 women with 
a twin pregnancy.20 While there was no significant effect 
in the overall population, pessary significantly reduced 
PTB <28 weeks and <32 weeks, median of time to delivery 
and adverse neonatal outcomes in women with a short 
cervix (<25% percentile, equal to 38 mm). These findings 
were further confirmed by another RCT performed by 
Goya et al.21 However, evidence supporting the futility of 
cervical pessary in women with twin pregnancies and a 
short cervix appeared in subgroup analyses of two RCTs, 
including an early- stopped one.22 23
Trials that directly compare cerclage, progesterone and 
pessary are limited. We recently compared the effective-
ness of cervical pessary and 400 mg progesterone daily 
in a RCT among women with twin pregnancies and a CL 
<38 mm.24 In our study, the primary outcome, PTB <34 
weeks, was comparable between the two groups. However, 
other secondary outcomes, including neonatal outcomes, 
were significantly improved in women treated with pessary. 
Moreover, in women with a CL ≤28 mm (25th percentile of 
randomised women), the rate of PTB <34 weeks significantly 
reduced from 54.5% in the progesterone group to 24.2% in 
the pessary group.24 A recent cost- effective analysis showed 
that pessary significantly improves the rate of morbidity- free 
survival neonate while reducing costs as compared with 
vaginal progesterone.25 As these data showed that cervical 
pessary might be superior to vaginal progesterone in the 
prevention of PTB in women with twin pregnancies and 
a CL ≤28 mm, the question that arises now is how cervical 
pessary compares to cervical cerclage. We therefore propose 
the Pessary versus Cerclage with or without Progesterone 
in Twins (PCP- Twins) study, in which we will compare the 
effectiveness of cervical pessary and cervical cerclage with 
or without vaginal progesterone to prevent PTB in women 
with twin pregnancies and a CL ≤28 mm.
MEthodS And AnAlySIS
Study design and ethical considerations
The PCP- Twins study is a randomised controlled trial and 
will be conducted at My Duc Hospital and My Duc Phu 
Nhuan Hospital, Ho Chi Minh City, Vietnam, according 
to the principles outlined in the Declaration of Helsinki 
and its amendments, in accordance with the Medical 
Research Involving Human Subjects Act (WMO) and 
using Good Clinical Practice. The trial has been approved 
by the Institutional Ethics Committee (IEC) of My Duc 
Hospital (02/2019/MĐ-HĐĐĐ).
It is our daily practice that all pregnant women will 
undergo urine culture for screening of asymptomatic 
bacteriuria in the first prenatal visit. If they have asymp-
tomatic bacteriuria, they will be treated with antibiotics.26 
At 16–22 weeks of gestation, asymptomatic women with 
twin pregnancies will undergo CL measurement and digital 
examination as part of routine clinical care. In case where 
vaginitis is suspected, vaginal culture could be performed. 
For women who conceived after ART, gestational age will be 
determined by the date of embryo transfer or intrauterine 
insemination. For those who conceived naturally, gesta-
tional age will be determined from the menstrual history 
and confirmed by the fetal crown- rump length of the larger 
twin at the first- trimester ultrasound examination. CL will 
be measured transvaginally in each hospital by two ultra-
sonographers certificated by the Fetal Medicine Founda-
tion. Prior to CL measurement, women will be given a short 
brochure outlining risk factors and available PTB preven-
tion methods.
A review of participant information will be done prior to 
enrolment to determine preliminary eligibility according 
to participant inclusion and exclusion criteria. Eligible 
participants will be screened by midwives or gynaecolo-
gists, then they will be provided a full participant infor-
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Figure 1 Flow of participants.
discussion with investigators about the study. All eligible 
women will be invited to participate in the study.
After written informed consent, women will be randomly 
assigned in a 1:1:1:1 ratio to receive a cerclage, pessary, 
cerclage plus progesterone or pessary plus progesterone. 
Assignment to treatment allocation will be done via a web 
portal hosted by HOPE Research Center, Vietnam. The 
randomisation schedule will be computer- generated at 
HOPE Research Center, with a permuted random block 
size of 4 or 8 (figure 1). Blinding will not be possible due 
to the nature of interventions. However, neonatologists 
assessing the children will be unaware of treatment allo-
cation. Apart from randomisation, participants will be 
followed up and treated according to local protocol. The 
study is currently recruiting, with first patient in was on 
23 March 2019 and an estimated duration of 36 months.
Participation in the study is voluntary. When a partici-
pant signs an informed consent, she is considered to be 
enrolled into the study. Participants can leave the study 
at any time for any reason, if they wish to do so without 
any consequences for their treatment. The investigator 
can decide to withdraw a subject from the study for 
urgent medical reasons. After randomisation, if a partic-
ipant wishes to change her assigned protocol, she will 
be considered as a cross- over subject. All subjects will be 
remained in the study for analysis based on intention to 
treat principle.
To maximise retention in the trial, consultation will 
be available to patients to ensure that they understand 
the procedures well and to address any questions or 
complaints that arise during the study.
Patients and public involvement
Patients and/or public were not involved in the study 
design and study enrolment.
Participants
Women aged ≥18 years, having twin pregnancies and CL 
≤28 mm measured at 16–22 weeks’ gestation, will be eligible 
for the study irrespective of chorionicity. Exclusion criteria: 
(1) women with uterine anomalies; (2) cervical dilation 
with visible amniotic membranes or amniotic membranes 
prolapsed into the vagina; (3) twin- to- twin transfusion 
syndrome; (4) stillbirth; (5) major congenital abnormal-
ities in any of the fetuses; (6) severe vaginal discharge; 
(7) acute vaginitis or cervicitis; (8) vaginal bleeding or 
placenta preavia or vasa preavia; (9) premature rupture of 
membranes or premature labour with/without ruptured 
membrane; (10) suspicion of chrorioaminitis; (11) cerclage 
or pessary in place or unable to undergo cervical cerclage or 
pessary placement. However, women with acute cervicitis, 
vaginitis or severe vaginal discharge are eligible once they 
have been treated and if they have a CL ≤28 mm between 
16 and 22 weeks.
treatment groups
Participants will be allocated to receive a cerclage, pessary, 
cerclage plus progesterone or pessary plus progesterone. 
Women allocated to a cervical cerclage will be receiving 
the intervention according to local protocol, within a week 
after randomisation. Briefly, two to three senior clinicians at 
each site who had experienced with cerclage will perform 
cervical cerclage, using Mc Donald technique, under spinal 
anaesthesia, in the operation theatre. Cephazolin 1 g will 
be given intravenously at 1 hour before cerclage as prophy-
lactic antibiotics.27
Pessary, a soft, flexible, silicone pessary, purchased from 
the manufacturer (Arabin, Dr Arabin GmbH & Co KG, 
Germany), will be inserted through the vagina, upward 
around the cervix by four senior clinicians, who had expe-
rienced with pessary placement, within 1 week of rando-
misation. The size of the pessary will be determined at the 
time of speculum inspection.28
In the cerclage plus progesterone group and pessary 
plus progesterone group, 400 mg vaginal progesterone, 
purchased from the manufacturer (Cyclogest 400 mg, 
Actavis, UK), will be applied once daily at bedtime, within 
2 days after cerclage insertion. Participants will be asked 
to record their drug application in a participant diary 
sheet for up to 147 days.
In all groups, participants will be reassessed at 14 days 
post randomisation for any possible adverse events. After 
that, participants will be seen monthly or weekly per local 
protocol. CL measurement will not be performed routinely 
after randomisation, unless for participants’ preference. In 
case of CL shortens after receiving allocated interventions, 
patient can be treated with a combination protocol taking 
additional interventions, for example, adding progesterone 
or pessary/cerclage, based on the discretion of treating 
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Table 1 Definition of neonatal outcomes
Secondary endpoint Definition
Respiratory distress syndrome (RDS) The presence of tachypnoea >60/min, sternal recession and expiratory grunting, need for 
supplemental oxygen and a radiological picture of diffuse reticulogranular shadowing with an 
air bronchogram.
Intraventricular haemorrhage II B or 
worse
Repeated neonatal cranial ultrasound by the neonatologist according to the guidelines on 
neuroimaging described by de Vries et al.
Necrotising enterocolitis (NEC) Will be diagnosed according to Bell.
Proven sepsis Will be diagnosed on the combination of clinical signs and positive blood cultures.
Stillbirth A baby born with no signs of life at or after 28 weeks’ gestation (WHO).
Composite of poor perinatal outcomes Fetal or neonatal death, intraventricular haemorrhage, RDS, NEC or neonatal sepsis.
case of premature rupture of the membranes, active vaginal 
bleeding, other signs of preterm labour or severe partici-
pant discomfort, the vaginal progesterone and pessary or 
cerclage will be removed. If participants develop (threat-
ened) preterm labour, they will receive treatment per local 
protocol. Intervention will be stopped at 370/7 weeks of 
gestation or at delivery if none of the above- stated condi-
tions happen.
At every visit, participant compliance with progesterone 
therapy will be documented by checking the participant 
diary and drug purchasing records from the hospital 
pharmacy. The compliance rate will be calculated by 
dividing the number of progesterone doses used since 
the previous visit by the number of progesterone doses 
that should have been used. Women will be defined as 
being in compliance when the compliance rate is equal 
or higher than 80%.
outcomes
Primary outcome
The primary outcome will be PTB <34 weeks’ gestation 
for any indication.
Secondary outcomes
Secondary outcomes will be fetal death before 24 weeks of 
gestation; stillbirth (defined as a fetus born with no signs 
of life at or after 28 weeks of gestation); delivery before 24, 
28, 32 and 37 weeks of gestation; labour induction, delivery 
mode, live birth; tocolytic drugs, antenatal corticosteroids 
or MgSO4 for neuroprotection use; admission days for 
preterm labour; preterm premature rupture of membrane 
chorioamnionitis; maternal side effects (including vaginal 
discharge, fever, vaginal infection or pain, pessary reposi-
tioning and necrosis or rupture of the cervix); maternal 
morbidity (including thromboembolic complications, 
urinary tract infection treated with antibiotics, pneumonia, 
endometritis, hypertensive disorder, eclampsia, haemo-
lysis, elevated liver enzymes, low platelet count syndrome, 
death); birth weight; birth weight less than 1500 g and less 
than 2500 g; congenital anomalies diagnosed after rando-
misation; 5 min Apgar score; 5 min Apgar score less than 
7; perinatal death, neonatal intensive care unit (NICU) 
admission; days of admission to the NICU; intraventric-
ular haemorrhage; respiratory distress syndrome; necro-
tising enterocolitis; proven sepsis and a composite of poor 
perinatal outcomes. Full definitions of these terms are 
provided in table 1.
Safety
The primary investigator will inform subjects and the 
reviewing accredited medical research ethics committee 
if anything occurs that would suggest that the disadvan-
tages of participation may be significantly greater than 
was foreseen in the research proposal. The study will 
be suspended pending further review by the accredited 
medical research ethics committee, except where suspen-
sion would jeopardise the participants’ health. The inves-
tigator will ensure that all subjects are kept informed.
Adverse events are defined as any undesirable experi-
ence occurring to a subject during a clinical trial, whether 
or not considered related to the intervention. All adverse 
events reported spontaneously by the subject or observed 
by the investigator or their staff will be recorded.
A serious adverse event (SAE) is defined as any untoward 
medical occurrence or effect that results in death, is life 
threatening (at the time of the event), requires hospitalisa-
tion or prolongation of an existing hospitalisation, results in 
persistent or significant disability or incapacity, is a congen-
ital anomaly or birth defect, is a new event of the trial likely 
to affect the safety of the subjects such as an unexpected 
outcome of an adverse reaction. All SAEs will be reported 
to the accredited ethics committee that approved the 
protocol, according to the requirements of that committee.
All adverse events will be followed until they have abated 
or until a stable situation has been reached. Depending 
on the event, follow- up may require additional tests or 
medical procedures as indicated and/or referral to a 
general physician or medical specialist.
Sample size calculation
This study is not to be powered to assess interactions 
between interventions. The rate of PTB <34 weeks of 
gestation in women with twin pregnancies and a cervix 
≤28 mm and treated with pessary in our previous Arabin 
versus Progesterone (AP) study at My Duc Hospital was 
24.2%.24 In order to show that cervical cerclage decreases 
the PTB rate by 50% (from 24.2% to 12.1%), we need 
to randomise 320 women (α level 0.05, power 80%). 
The rate of PTB <34 weeks of gestation in women with 
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progesterone at My Duc Hospital was 54.5%.24 There-
fore, the statistical power to study the effect of proges-
terone by randomising 320 women is 80% (α level 0.05, 
PTB rate in progesterone group 54.5%, PTB rate in non- 
progesterone group 39.0%). Considering a 5% lost to 
follow- up and protocol deviation, we plan to recruit 340 
participants (85 per arm).
Confidentiality and ownership of trial data
VQD, LMTN and LNV will have access to the final trial 
dataset. Any confidential information relating to the trial, 
including any data and results from the trial, will be the 
exclusive property of My Duc Hospital. The investigators 
and any other persons involved in the trial will protect the 
confidentiality of this proprietary information belonging 
to My Duc Hospital.
Statistical analysis
Statistical analysis will be conducted according to the 
intention- to- treat principle, in which all randomised 
women will be considered in the primary comparison 
between treatment groups. The per- protocol analysis 
may be conducted, but these results would be considered 
exploratory only. All tests will be two tailed and differ-
ences with p value <0.05 will be considered statistically 
significant. In view of the two- by- two factorial design, the 
analysis will be done separately for cerclage versus pessary 
and for progesterone versus no progesterone. No adjust-
ments are planned for multiple comparisons.
Baseline characteristics will be described by descriptive 
analysis (mean and SD for normally distributed variables 
or median and IQR for skewed variables). For categor-
ical variables, we will present the proportions (%) of the 
four arms. In addition, we will also report the numbers 
of recruitment, participants lost to follow- up, protocols 
violation and other relevant descriptive data.
The primary outcome, PTB <34 weeks’ gestation, will 
be compared using Pearson’s χ2 test or Fisher’s exact test 
for unadjusted analysis. We will also compute unadjusted 
risk ratio (RR) and its 95% CI. In the event of prominent 
imbalance of potential confounders between arms, we will 
perform multivariable log–binomial or Poisson regres-
sion with robust variance estimate to compute adjusted 
RR and its 95% CI.
For continuous variables, results will be given as mean 
(SD) and between- group differences will be assessed using 
Student’s t- test. For dichotomous endpoints, Relative Risk 
and 95% CI values will be calculated. Time to delivery 
will be assessed using a Cox proportional hazard analysis 
and Kaplan- Meier estimates, where gestational age will be 
the time scale, birth will be the event and results will be 
compared with a log- rank test. HR values will be estimated 
using a Cox proportional hazards model, with a formal 
test of the proportional hazards assumption. For neonatal 
outcomes, we will use cluster analysis taking into account 
the dependency between the twins.29 We plan a prespeci-
fied subgroup analysis in: (1) women with different chorio-
nicity and (2) women with a CL <25th percentile and at the 
25–50th percentile, 50–75th percentile and >75th percen-
tile. The percentile will be determined based on the CL 
from all women after randomisation. We will test for inter-
action between CL and treatment effect on PTB <34 weeks 
and the composite of poor perinatal outcomes. Interaction 
between groups of interventions will also be tested due to 
the 2×2 factorial design of our randomised controlled trial. 
However, the tests for interactions will be exploratory.
Interim analysis and monitoring
We will establish an independent Data Safety Monitoring 
Committee (DSMC) to review and interpret data generated 
from the study and to review revisions of the protocol prior 
to their implementation. The roles and responsibilities, 
including the timing of meetings, methods of providing 
information to and from the DSMC, frequency and format 
of meetings, statistical issues and relationships with other 
committees are described in the DSMC charter (online 
supplementary appendix 1).
All SAEs will be reported to the IEC within 15 working 
days. Life- threatening SAEs or an event that leads to death 
will be reported to the IEC immediately. All SAEs will be 
followed until they have abated, until a stable situation 
has been reached or the patient is discharged. Due to the 
nature of interventions, we do not expect to terminate the 
study prematurely.
We plan one interim analysis. The interim analysis will 
be performed by an independent statistician who will not 
directly involve in the study, after completion of data collec-
tion of the first 150 randomised participants. At interim 
analysis, data will be assessed for safety, efficacy and futility. 
Safety will be assessed in terms of SAEs (perinatal death, 
maternal mortality or severe maternal morbidity). The 
interim analysis will be conducted using a two- sided signif-
icant test with the Haybittle- Peto spending function and 
a type I error rate of 5% (final alpha level) with stopping 
criteria of p<0.001 (Z alpha=3.29). Based on this report, 
the DSMC will provide guidance on whether to stop or 
continue the study.
data handling
Data will be collected using a questionnaire and recorded 
with Epi Info software (Centers for Disease Control and 
Prevention). Data of each visit will be documented in the 
participant’s study profile. When the participant attends 
for delivery, data on labour, delivery and any complica-
tions experienced by participant and the neonates will be 
collected. For those who do not continue to follow- up at 
either site, for any reasons, we will contact the participants 
via telephone/email monthly until birth to collect data. 
We also ask these participants to scan their profile in every 
contact.
All data will be entered into the database twice. The first 
data entry will be made within a day after randomisation. 
The second will undertake at the termination of the study. 
Data from the two entries will be checked and adjudicated 
by independent data monitoring using the original partici-
pant medical record. Participant privacy will be ensured by 















pen: first published as 10.1136/bm




6 Dang VQ, et al. BMJ Open 2020;10:e036587. doi:10.1136/bmjopen-2019-036587
Open access 
will be used on all study documentation, with the partici-
pant code only available to the local investigator.
Independent study monitoring will be performed 
monthly at each site by a clinical research associate from 
HOPE Research Center to ensure adherence to the 
protocol, International Conference on Harmonisation—
Good Clinical Practice, standard operating procedures and 
applicable regulatory requirements, maintenance of trial- 
related source records, completeness, accuracy and verifi-
ability of case report form entries compared with source 
data.
Missing data
For missing values regarding baseline characteristics, we 
will first perform analysis by excluding missing values; we 
will then perform multiple imputations to impute missing 
values and conduct subsequent analysis to estimate the 
robustness of the findings. For the loss of follow- up and 
protocol deviation, we will attempt sensitive analyses to 
explore the effect of these factors on the trial findings.
End of study
We estimate an expected duration of 36 months, with 
expected final recruitment at March 2022. The principal 
investigator will notify the IEC of My Duc Hospital of the 
end of the study within a period of 90 days. The end of the 
study is defined as the last participant’s last visit. In the event 
of early study termination, the principal investigator will 
notify the IEC of My Duc Hospital within 15 days, including 
the reasons for premature termination.
Ethics and dissemination
Any change to the study protocol will be documented in 
a protocol amendment. Amendments are submitted for 
consideration to the approving ethics committee (the 
IEC of My Duc Hospital). If new information becomes 
available that may be relevant to a subject’s willingness 
to continue participation in the trial, a new subject infor-
mation and informed consent form will be forwarded to 
the ethics committee. The trial subjects will be informed 
about this new information and reconsent will be obtained. 
Changes will be updated on trial registration website  clin-
icaltrials. gov. Changes to the protocol to eliminate imme-
diate hazard(s) to trial subjects may be implemented prior 
to ethics committee approval or receipt of a favourable 
opinion.
No specific arrangements will be made between any spon-
sors and the investigator concerning the public disclosure 
and publication of the research data. The principle investi-
gator will prepare a manuscript detailing the results of the 
main study as soon as appropriate and submit this to a peer- 
reviewed medical journal. Supplementary analyses will be 
analysed and reported separately.
dISCuSSIon
It has been shown that women with twin pregnancies and a 
short cervix are at extremely high risk for PTB.13 Therefore, 
prevention of PTB has become priority in healthcare for 
mothers and children.
In this study, we choose to compare two interventions 
directly to each other. While we appreciate that when 
interventions are introduced, they should be compared 
with expectant management or placebo, this has already 
been done in a large number of twins, for both cervical 
pessary20 21 23 and progesterone.15 Our recent trial showed 
that compared with vaginal progesterone, the use of pessary 
in women with twin pregnancies and a short cervix improved 
neonatal outcomes. Moreover, in women with a CL  ≤ 28 mm 
(25th percentile of CL distribution), the rate of PTB <34 
weeks reduced from 54.5% in the progesterone group to 
24.2% in the pessary group.24 In addition, recent small 
retrospective studies showed that cerclage could lower PTB 
rates and could improve neonatal outcomes.30–32 These data 
suggest that any of the two treatments could reduce the risk 
of PTB and subsequent poor neonatal outcome. The aim of 
clinical research is not to directly prove in a purely scientific 
setting whether a treatment works over no treatment, but 
to show which is the best for patients. In view of the large 
differences that we found for pessary versus progesterone24 
and others found for pessary and progesterone against no 
treatment,15 20 21 we render it from an ethical point chal-
lenging to compare these treatments to expectant manage-
ment or placebo. This approach can also be found in other 
ongoing trials.33 34
The cut- off value for CL in twins is still controversial and 
varies from study to study, with 25 mm being used in some 
studies.21 31 35 However, the association between CL and the 
risk of PTB is unlikely to be ‘all or none’ with this cut- off. In 
this trial, we choose 28 mm as a cut- off based on a preplanned 
subgroup analysis of our previous RCT that reported that 
in patients with a CL ≤25th percentile (≤28 mm), the use 
of pessary was associated with a significant reduction in the 
risk of PTB <34 weeks, PTB <37 weeks and the risk of poor 
perinatal outcomes.24 There is scarce evidence regarding 
the management of women with a CL between 25 mm and 
28 mm, who are likely to have an elevated risk of PTB. Only 
by including women below a cut- off 28 mm, we will be able 
to understand how pessary compares to cerclage in women 
with a CL between 25 mm and 28 mm. Meanwhile, we would 
be able to perform a subgroup analysis confining to those 
with a CL ≤25 mm.
Strengths of this trial include its randomised, controlled 
design, which should minimise bias and a multicentre 
design, which enhance the generalisability of the results. 
Moreover, there will be a limited number of well trained, 
certified staffs who will involve in CL measurement, pessary 
and cerclage placement. This can help to increase the 
validity of the study. However, an open design, which is 
unavoidable due to the nature of the interventions, could 
introduce bias. The external validity of the study might be 
compromised since the majority of women with twin preg-
nancies involving in the trial will conceive from ART.
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